Data as of Jan 28
| 0.00 / 0.00%|
Vericel Corp. is a regenerative medicine company which engages in the development of patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. The company's research and product development involves in the development of patient specific cell products for use in regenerative medicine. Its proprietary cell-manufacturing technology enables the manufacture of Ixmyelocel-T, a patient-specific, multicellular therapy, expanded from an adult's own bone marrow, and delivered directly to damaged tissues. Vericel was founded on March 24, 1989 and is headquartered in Cambridge, MA.
|Dominick C. Colangelo||President, CEO, Treasurer, Director & CAO|
|Daniel R. Orlando||Chief Operating Officer|
|Gerard J. Michel||Chief Financial Officer & VP-Corporate Development|
|David Recker||Chief Medical Officer|
|Ross Tubo||Chief Scientific Officer|